Second-line treatments of small-cell lung cancers

References

• Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–4544. [PubMed: 17008692].
   PubMed Web of Science ®Google Scholar
• Behera M, Ragin C, Kim S, et al. Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer. 2016;122:50–60.
   PubMed Web of Science ®Google Scholar
• Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with five years’ follow-up. J Clin Oncol. 2002;20:4665–4672. [PubMed: 12488411].
   PubMed Web of Science ®Google Scholar
• Pujol JL, Daurès JP, Rivière A, et al. Etoposide plus cisplatin with or without the combination of 4ʹ-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institute multicenter phase III randomized study. J Natl Cancer Inst. 2001;93:300–308. [PubMed:11181777].
   PubMedGoogle Scholar
• O’Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441–5447. [PubMed: 17135646].
   PubMed Web of Science ®Google Scholar
• Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–667. [PubMed: 10080612].
   PubMed Web of Science ®Google Scholar
• Eckardt JR, Von Pawel J, Pujol J-L, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. Journal of Clinical Oncology. 2007;25: 2086–2092. [PubMed: 17513814].
   PubMed Web of Science ®Google Scholar
• Von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32:4012–4019. [PubMed: 25385727].
   PubMed Web of Science ®Google Scholar
• Goto K, Ohe Y, Shibata T, et al. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2016;17:1147–1157. [PubMed: 27312053].
   PubMed Web of Science ®Google Scholar
• Kim YH, Goto K, Yoh K, et al. Performance status and sensitivity to first-line chemotherapy are significant prognostic factors in patients with recurrent small cell lung cancer receiving second-line chemotherapy. Cancer. 2008;113:2518–2523. [PubMed: 18780323].
   PubMed Web of Science ®Google Scholar
• Giaccone G, Donadio M, Bonardi G, et al. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 1988;6:1264–1270. [PubMed: 2842464].
   PubMed Web of Science ®Google Scholar
• Postmus PE, Berendsen HH, Van Zandwijk N, et al. Retreatment with the induction regimen in small cell lung cancer relapsing after initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23:1409–1411. [PubMed: 2824211].
   PubMedGoogle Scholar
• Owonikoko TK, Behera M, Chen Z, et al. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7:866–872. [PubMed: 22722788].
   PubMed Web of Science ®Google Scholar
• Von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 2001;19:1743–1749. [PubMed: 11251005].
   PubMed Web of Science ®Google Scholar
• Jalal S, Ansari R, Govindan R, et al. Pemetrexed in second line and beyond small cell lung cancer: a Hoosier Oncology Group phase II study. J Thorac Oncol. 2009;4:93–99. [PubMed: 19096313].
   PubMed Web of Science ®Google Scholar
• Socinski MA, Raju RN, Neubauer M, et al. Pemetrexed in relapsed small-cell lung cancer and the impact of shortened vitamin supplementation lead-in time: results of a phase II trial. J Thorac Oncol. 2008;3:1308–1316. [PubMed: 18978567].
   PubMed Web of Science ®Google Scholar
• Gronberg BH, Bremnes RM, Aasebo U, et al. A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer. 2009;63:88–93. [PubMed: 18538889].
   PubMed Web of Science ®Google Scholar
• Hoang T, Kim K, Jaslowski A, et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer. 2003;42:97–102. [PubMed: 14512193].
   PubMed Web of Science ®Google Scholar
• Van Der Lee I, Smit EF, Van Putten JW, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol. 2001;12:557–561. [PubMed: 11398892].
   PubMed Web of Science ®Google Scholar
• Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: eastern cooperative oncology group trial 1597. J Clin Oncol. 2003;21:1550–1555. [PubMed: 12697880].
   PubMed Web of Science ®Google Scholar
• Furuse K, Kubota K, Kawahara M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group. Oncology. 1996;53:169–172. [PubMed: 8604245].
   PubMed Web of Science ®Google Scholar
• Jassem J, Karnicka-Młodkowska H, Van Pottelsberghe C, et al. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1993;29A:1720–1722. [PubMed: 8398301].
   PubMed Web of Science ®Google Scholar
• Schmittel A, Knödler M, Hortig P, et al. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients. Lung Cancer. 2007;55:109–113. [PubMed: 17097191].
   PubMed Web of Science ®Google Scholar
• Lammers PE, Shyr Y, Li CI, et al. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small cell lung cancer. J Thorac Oncol. 2014;9:559–562. [PubMed: 24736081].
   PubMed Web of Science ®Google Scholar
• Rhee CK, Lee SH, Kim JS, et al. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer. Lung Cancer. 2011;72:64–67. [PubMed: 20832894].
   PubMed Web of Science ®Google Scholar
• Kim GM, Kim YS, Ae Kang Y, et al. Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients. J Thorac Oncol. 2012;7:731–736. [PubMed: 22425922].
   PubMed Web of Science ®Google Scholar
• Jeong J, Cho BC, Sohn JH, et al. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. Lung Cancer. 2010;70:77–81. [PubMed: 20138389].
   PubMed Web of Science ®Google Scholar
• Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225–1229. [PubMed: 1321891].
   PubMed Web of Science ®Google Scholar
• Smit EF, Fokkema E, Biesma B, et al. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77:347–351. [PubMed: 9461009].
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Tsurutani J, Yoshimura N, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res. 2006;26:777–781. [PubMed: 16739353].
   PubMed Web of Science ®Google Scholar
• Evans TL, Cho BC, Udud K, et al. Cabazitaxel versus topotecan in patients with small-cell lung cancer with progressive disease during or after first-line platinum-based chemotherapy. J Thorac Oncol. 2015;10:1221–1228. [PubMed: 26200278].
   PubMed Web of Science ®Google Scholar
• Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol. 2009;27:2046–2051. [PubMed: 19289620].
   PubMed Web of Science ®Google Scholar
• Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012;18:1138–1145. [PubMed: 22228633].
   PubMed Web of Science ®Google Scholar
• Zauderer MG, Drilon A, Kadota K, et al. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer. 2014;86:237–240. [PubMed: 25194640].
   PubMed Web of Science ®Google Scholar
• Krug LM, Crawford J, Ettinger DS, et al. Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. J Thorac Oncol. 2011;6:384–386. [PubMed: 21252718].
   PubMed Web of Science ®Google Scholar
• Lycan TW, Pardee TS, Petty WJ, et al. A phase II clinical trial of CPI 613 in patients with relapsed or refractory small cell lung carcinoma. PloS One. 2016;11:e0164244.
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Nishio M, Satouchi M, et al. A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy. Lung Cancer. 2016;100:20–23. [PubMed: 27597276].
   PubMed Web of Science ®Google Scholar
• Kubota K, Nishiwaki Y, Kakinuma R, et al. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol. 1997;15:292–296. [PubMed: 8996155].
   PubMed Web of Science ®Google Scholar
• Goto K, Sekine I, Nishiwaki Y, et al. Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung. cancer. Br J Cancer. 2004;91:659–665. [PubMed: 15280919].
   PubMed Web of Science ®Google Scholar
• Fennell DA, Steele JP, Shamash J, et al. Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer. Int J Cancer. 2007;121:2575–2577. [PubMed: 17680556].
   PubMed Web of Science ®Google Scholar
• Faylona EA, Loehrer PJ, Ansari R, et al. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial. J Clin Oncol. 1995;13:1209–1214. [PubMed: 7738623].
   PubMed Web of Science ®Google Scholar
• Kosmas C, Tsavaris NB, Malamos NA, et al. Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer. J Clin Oncol. 2001;19:119–126. [PubMed: 11134204].
   PubMed Web of Science ®Google Scholar
• Leighl NB, Goss GD, Lopez PG, et al. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer. 2006;52:327–332. [PubMed: 16597474].
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Manegold C, Debruyne C, et al. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res. 2003;9:143–150. [PubMed:12538462].
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Kalofonos HP, Briasoulis E, et al. Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Cancer Chemother Pharmacol. 2006;57:207–212. [PubMed: 16028103].
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Christodoulou CH, Stathopoulos J, et al. Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study. Cancer Chemother Pharmacol. 2006;57:796–800. [PubMed: 16142488].
   PubMed Web of Science ®Google Scholar
• Dy GK, Jett JR, Geoffroy FJ, et al. Topotecan and paclitaxel in previously treated patients with relapsed small cell lung cancer: phase II trial of the north central cancer treatment group. J Thorac Oncol. 2006;1:211–217. [PubMed: 17409859].
   PubMed Web of Science ®Google Scholar
• Hobdy EM, Kraut E, Masters G, et al. A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer. Cancer Biol Ther. 2004;3:89–93. [PubMed: 14726661].
   PubMed Web of Science ®Google Scholar
• Nogami N, Hotta K, Kuyama S, et al. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401. Lung Cancer. 2011;74:80–84. [PubMed: 21334093].
   PubMed Web of Science ®Google Scholar
• Hirose T, Nakashima M, Shirai T, et al. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer. Lung Cancer. 2011;73:345–350. [PubMed: 21277039].
   PubMed Web of Science ®Google Scholar
• Rocha-Lima CM, Herndon JE 2nd, Lee ME, et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann Oncol. 2007;18:331–337. [PubMed: 17065590].
   PubMed Web of Science ®Google Scholar
• Schuette W, Nagel S, Juergens S, et al. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Clin Lung Cancer. 2005;7:133–137. [PubMed: 16179101].
   PubMed Web of Science ®Google Scholar
• Agelaki S, Syrigos K, Christophylakis C, et al. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Oncology. 2004;66:192–196. [PubMed: 15218309].
   PubMed Web of Science ®Google Scholar
• Ando M, Kobayashi K, Yoshimura A, et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell. Lung Cancer. Lung Cancer. 2004;44:121–127. [PubMed: 15013590].
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Takayama K, Takano K, et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol. 1999;22:399–402. [PubMed: 10440199].
   PubMed Web of Science ®Google Scholar
• Naka N, Kawahara M, Okishio K, et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer. 2002;37:319–323. [PubMed: 12234702].
   PubMed Web of Science ®Google Scholar
• Ichiki M, Gohara R, Rikimaru T, et al. Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: a phase II study. Chemotherapy. 2003;49:200–205. [PubMed: 12886056].
   PubMed Web of Science ®Google Scholar
• Hirose T, Horichi N, Ohmori T, et al. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer. 2003;40:333–338. [PubMed: 12781433].
   PubMed Web of Science ®Google Scholar
• Masuda N, Matsui K, Negoro S, et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1998;16:3329–3334. [PubMed: 9779709].
   PubMed Web of Science ®Google Scholar
• Xenidis N, Vardakis N, Varthalitis L, et al. Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Cancer Chemother Pharmacol. 2011;68:63–68. [PubMed: 20830475].
   PubMed Web of Science ®Google Scholar
• Groen HJ, Fokkema E, Biesma B, et al. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule. J Clin Oncol. 1999;17:927–932. [PubMed: 10071286].
   PubMed Web of Science ®Google Scholar
• Kakolyris S, Mavroudis D, Tsavaris N, et al. Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol. 2001;12:193–197. [PubMed: 11300323].
   PubMed Web of Science ®Google Scholar
• Yun T, Kim HT, Han JY, et al. A phase II study of weekly paclitaxel plus gemcitabine as a second-line therapy in patients with metastatic or recurrent small cell lung cancer. Cancer Res Treat. 2016;48:465–472. [PubMed: 26044164].
   PubMedGoogle Scholar
• Dazzi C, Cariello A, Casanova C, et al. Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study. Clin Lung Cancer. 2013;14:28–33. [PubMed: 22537509].
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Ansari R, Walker P, et al. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group trial. Am J Clin Oncol. 2000;23:68–70. [PubMed: 10683082].
   PubMed Web of Science ®Google Scholar
• Johnson E, Lake D, Herndon JE 2nd, et al. Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332. Am J Clin Oncol. 2004;27:19–23. [PubMed: 14758128].
   PubMed Web of Science ®Google Scholar
• Rapti A, Agelidou A, Stergiou I, et al. Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: a multicentre phase II study. Lung Cancer. 2005;49:241–244. [PubMed: 16022918].
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Burris HA 3rd, Erland JB, et al. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Invest. 2003;21:193–199. [PubMed: 12743984].
   PubMed Web of Science ®Google Scholar
• Dudek AZ, Lesniewski-Kmak K, Bliss RL, et al. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer. Lung. 2005;183:43–52. [PubMed: 15793666].
   PubMed Web of Science ®Google Scholar
• Lebeau B, Chouaïd C, Baud M, et al. Oral second- and third-line lomustine–etoposide–cyclophosphamide chemotherapy for small cell lung cancer. Lung Cancer. 2010;67:188–193. [PubMed: 19394109].
   PubMed Web of Science ®Google Scholar
• Gervais R, Le Caer H, Monnet I, et al. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501. Clin Lung Cancer. 2015;16:100–105. [PubMed: 25467927].
   PubMed Web of Science ®Google Scholar
• Pleasance ED, Stephens PJ, O’Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463:184–190. [PubMed: 20016488].
   PubMed Web of Science ®Google Scholar
• Jalal S, Bedano P, Einhorn L, et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol. 2010;5:2008–2011. [PubMed: 21102263].
   PubMed Web of Science ®Google Scholar
• Mountzios G, Emmanouilidis C, Vardakis N, et al. Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group. Lung Cancer. 2012;77:146–150. [PubMed: 22418242].
   PubMed Web of Science ®Google Scholar
• Spigel DR, Waterhouse DM, Lane S, et al. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Clin Lung Cancer. 2013;14:356–363. [PubMed: 23391616].
   PubMed Web of Science ®Google Scholar
• Trafalis DT, Alifieris C, Stathopoulos GP, et al. Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer. Cancer Chemother Pharmacol. 2016;77:713–722. [PubMed: 26891956].
   PubMed Web of Science ®Google Scholar
• Allen JW, Moon J, Redman M, et al. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014;32:2463–2470. [PubMed: 25002722].
   PubMed Web of Science ®Google Scholar
• Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003;9:5880–5887. [PubMed: 14676110].
   PubMed Web of Science ®Google Scholar
• Krug LM, Crapanzano JP, Azzoli CG, et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-KIT protein: a phase II clinical trial. Cancer. 2005;103:2128–2131. [PubMed: 15812822].
   PubMed Web of Science ®Google Scholar
• Dy GK, Miller AA, Mandrekar SJ, et al. A phase II trial of imatinib (ST1571) in patients with c-KIT expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol. 2005;16:1811–1816. [PubMed: 16087693].
   PubMed Web of Science ®Google Scholar
• Miller AA, Pang H, Hodgson L, et al. A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol. 2010;5:380–384. [PubMed: 20087228].
   PubMed Web of Science ®Google Scholar
• Lu HY, Zhang G, Cheng QY, et al. Expression and mutation of the c-KIT gene and correlation with prognosis of small cell lung cancer. Oncol Lett. 2012;4:89–93. [PubMed: 22807968].
   PubMed Web of Science ®Google Scholar
• Moore AM, Einhorn LH, Estes D, et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer. 2006;52:93–97. [PubMed: 16488055].
   PubMed Web of Science ®Google Scholar
• Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res. 2008;14:6092–6096. [PubMed: 18829487].
   PubMed Web of Science ®Google Scholar
• Chiappori AA, Otterson GA, Dowlati A, et al. A randomized phase II study of linsitinib (OSI-906) versus topotecan in patients with relapsed small-cell lung cancer. Oncologist. 2016;21:1163–1164. [PubMed: 27694157].
   PubMed Web of Science ®Google Scholar
• Gitlitz BJ, Moon J, Glisson BS, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol. 2010;5:1835–1840. [PubMed: 20881645].
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Belani CP, Mack PC, et al. Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol. 2010;5:1279–1284. [PubMed: 20559150].
   PubMed Web of Science ®Google Scholar
• Kotsakis A, Karavasilis V, Agelaki S, et al. Pazopanib as second line treatment of platinum sensitive SCLC patients: a multicenter phase II trial of the Hellenic Oncology Research Group. 16th World Conference on Lung Cancer. Denver, Colorado, USA. 6–9 Sept 2015.
   Google Scholar
• Tarhini A, Kotsakis A, Gooding W, et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res. 2010;16:5900–5907. [PubMed: 21045083].
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Chansky K, Davies AM, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol. 2006;1:996–1001. [PubMed: 17409985].
   PubMed Web of Science ®Google Scholar
• Baggstrom MQ, Qi Y, Koczywas M, et al. A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J Thorac Oncol. 2011;6:1757–1760. [PubMed: 3180914].
   PubMed Web of Science ®Google Scholar
• Paik PK, Rudin CM, Pietanza MC, et al. A phase II study of obatoclax mesylate, a BCL-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 2011;74:481–485. [PubMed: 21620511].
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18:3163–3169. [PubMed: 22496272].
   PubMed Web of Science ®Google Scholar
• Melichar B, Adenis A, Lockhart AC, et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. Lancet Oncol. 2015;16:395–405. [PubMed: 25728526].
   PubMed Web of Science ®Google Scholar
• Heymach JV, Johnson DH, Khuri FR, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol. 2004;15:1187–1193. [PubMed: 15277257].
   PubMed Web of Science ®Google Scholar
• Lucchi M, Mussi A, Fontanini G, et al. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg. 2002;21:1105–1110. [PubMed: 12048093].
   PubMed Web of Science ®Google Scholar
• Han JY, Kim HY, Lim KY, et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer. 2013;79:137–142. [PubMed: 23182663].
   PubMed Web of Science ®Google Scholar
• Han JY, Kim HY, Lim KY, et al. A phase II study of nintedanib in patients with relapsed small cell lung cancer. Lung Cancer. 2016;96:108–112. [PubMed: 27133759].
   PubMed Web of Science ®Google Scholar
• Iang SX, Sato Y, Kuwao S, et al. Expression of BCL-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol. 1995;177: 135–138. [PubMed: 7490679].
   PubMed Web of Science ®Google Scholar
• Sartorius UA, Krammer PH. Upregulation of BCL-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer. 2002;97: 584–592. [PubMed: 11807782].
   PubMed Web of Science ®Google Scholar
• Nakajima W, Sharma K, Hicks MA, et al. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer. Cancer Biol Ther. 2016;17:27–35. [PubMed: 26575826].
   PubMed Web of Science ®Google Scholar
• Wysong DR, Chakravarty A, Hoar K, et al. The inhibition of aurora A abrogates the mitotic delay induced by microtubule perturbing agents. Cell Cycle. 2009;8: 876–888. [PubMed: 19221504].
   PubMed Web of Science ®Google Scholar
• De Marinis F, Atmaca A, Tiseo M, et al. A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer. J Thorac Oncol. 2013;8:1091–1094. [PubMed: 23857399].
   PubMed Web of Science ®Google Scholar
• Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2:798–811. [PubMed: 22961666].
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Rafii S, Ramanathan RK, et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase I trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. J Clin Oncol. 2014;32(abstr):7522.
   Google Scholar
• Maria CP, Lee MK, Saiama NW, et al. A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs). J Clin Oncol. 2016;34:abstr 8512.
   Google Scholar
• Cardnell RJ, Feng Y, Diao L, et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013;19:6322–6328. [PubMed: 24077350].
   PubMed Web of Science ®Google Scholar
• Penton AL, Leonard LD, Spinner NB. Notch signaling in human development and disease. Semin Cell Dev Biol. 2012;23: 450–457. [PubMed: 22306179].
   PubMed Web of Science ®Google Scholar
• C M R, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42–51. [PubMed: 27932068].
   PubMed Web of Science ®Google Scholar
• Ishii H, Azuma K, Kawahara A, et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol. 2015;10:426–430. [PubMed 25384063].
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883–895. [PubMed: 27269741].
   PubMed Web of Science ®Google Scholar
• Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18:623–630. [PubMed: 28291584].
   PubMed Web of Science ®Google Scholar
• Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30:525–532. [PubMed: 22253462].
   PubMed Web of Science ®Google Scholar
• Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumour cells in small-cell lung cancer. Nat Med. 2014;20:897–903. [PubMed: 27869802].
   PubMed Web of Science ®Google Scholar
• Köhn L, Johansson M, Grankvist K, et al. Liquid biopsies in lung cancer-time to implement research technologies in routine care? Ann Transl Med. 2017;5: 278. [PubMed:28758104].
   PubMed Web of Science ®Google Scholar
• Gray JE, Heist RS, Starodub AN, et al. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting trop-2, sacituzumab govitecan. Clin Cancer Res. 2017 Jul 5:pii: clincanres.0933. [PubMed: 28679770].
   Google Scholar